The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...

Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...

The phase II DAZALS study evaluating Corcept's dazucorilant in patients with amyotrophic lateral sclerosis fails to meet the primary goal.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Researchers from the Structural Biology Brussels group at Vrije Universiteit Brussel (VUB) have uncovered a significant ...

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

Dewpoint Therapeutics Inc. and Mitsubishi Tanabe Pharma Corp. have entered a research collaboration worth up to $480 million ...

Therapeutics announced it has concluded a Type C meeting with the FDA for PrimeC in the treatment of amyotrophic lateral ...

Corcept's drug dazucorilant failed to meet its primary endpoint during a Phase 2 trial to slow the decline in motor and functional skills in patients with Amyotrophic Lateral Sclerosis, or ALS.

The research, led by the ALS Association in collaboration with several leading ALS clinicians, examined Medicare claims made from 2011 to 2021 and found that the average time for ...

The company’s lead asset, CNM-Au8, is showing potential efficacy in treating amyotrophic lateral sclerosis (ALS), with plans for a New Drug Application (NDA) filing in mid-2025. This move is backed by ...

Data from over 8,000 ALS patients will be fed into Unlearn's Digital Twin Generator, an AI platform that creates duplicates ...